Tag: life sciences
-
Alzheimer’s Digital Biomarkers Project Gains New Funds
A venture philanthropy group is funding an initiative to find digital data indicators of early onset of Alzheimer’s disease and other forms of dementia.
-
Biotech Opens Gene Therapy Manufacturing Facility
A biotechnology company serving gene therapy developers is opening a manufacturing facility for engineered viruses that deliver gene therapies.
-
Covid-19 Delta Variant Testing Reference Released
A company designing synthetic DNA and RNA says reference materials are available for tests that detect the quickly spreading Covid-19 delta variant.
-
Synthetic Blood Vessel Maker Gains $2.2M in Seed Funds
A start-up company creating synthetic blood vessels for transplants, based on research in materials science and cell biology, is raising $2.2 million in seed funds.
-
ALS Drug Maker Gains $135M in New Funds
A developer of treatments for people with amyotrophic lateral sclerosis, or ALS, is raising $135 million in its third venture financing round.
-
Pooled Saliva Tests Detect Covid-19 in Schools
Combining commercial saliva tests to speed detection of the SARS-CoV-2 virus in schools is shown as accurate as individual gold-standard nasal swab tests.
-
Trial to Test Antibody Drug for Alzheimer’s Prevention
Eli Lilly and Company is partnering with an Alzheimer’s disease research center to test a synthetic antibody for preventing the disorder in at-risk individuals.
-
$60M Challenge Seeks RNA Bio-Production Network
A new challenge competition aims to build a distributed network of facilities to design, develop, and manufacture RNA-based biologic products.
-
Precision Gene-Editing Biotech Gains $200M in New Funds
A biotechnology company says it discovers therapies with the gene-editing technique Crispr to carry out a wider range of precise genomic corrections.
-
Trial Underway for Crispr Lymphoma Therapy
A clinical trial enrolled its first participant testing the safety of a treatment for lymphoma, a type of cancer, using the gene-editing technique Crispr.